Relapsed or refractory multiple myeloma Cancer Relapsed or refractory multiple myeloma
Conditions
Interventions
Cetuximab (Erbitux) loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly by intravenous infusion.
Sponsors
University of Cologne (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Multiple myeloma diagnosed according to the Durie-criteria in stage II or III (Salmon and Durie) 2. Measurable disease 3. Refractory or relapsed disease after at least one line of treatment 4. Male or female 18 years of age or older 5. Life expectancy more than 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) performances status zero to two 7. If of childbearing potential, willingness to use effective contraceptive method for the study duration and six months post-dosing 8. No surgery, radiotherapy or chemotherapy or any investigational agent within four weeks of study entry 9. Signed written informed consent
Exclusion criteria
Exclusion criteria: 1. Asecretory multiple myeloma 2. Patients eligible and willing to undergo high dose chemotherapy followed by autologous stem cell transplantation 3. Prior allogenic transplantation 4. Prior antibody or Epidermal Growth Factor Receptor (EGFR)-pathway targeting therapy 5. Severe cardiovascular disease like functionally restricting heart rhythm disturbance or heart malformation or severe hypertension, or cardiac insufficiency more than the New York Heart Association-II 6. Human Immunodeficiency Virus (HIV) infection, Hepatitis B or C 7. Brain disorders, psychatric illness 8. Insufficient bone marrow reserve (leucocytes less than 1500/µl, thrombocytes less than 50000/µl) 9. Creatinine-clearance less than 50 ml/min or serum creatinine more than 1.8 mg/dl 10. Bilirubin more than 2 mg/dl, Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) more than 100 U/l 11. Pregnancy (absence confirmed by serum/urine Beta-Human Chorionic Gonadotropin [Beta-HCG]) or breast-feeding 12. Pulmonary dysfunction 13. Active secondary malignancy 14. Legal incapacity or limited legal capacity 15. Having participated in another clinical trial or any investigational agent in the preceding 30 days 16. Known allergic/hypersensitivity reaction to any compounds of the treatment 17. Other previous malignancy within five years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix 18. Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent 19. Known drug abuse/alcohol abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess efficacy of Cetuximab in patients with refractory/relapsed multiple myeloma. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Safety profile of Cetuximab with/without Dexamethasone 2. Freedom from treatment failure 3. Progression-free survival 4. Overall survival 5. Pharmacogenomic evaluation of response to treatment | — |
Countries
Germany
Outcome results
None listed